Baolingbao Biology Co.,Ltd. (SHE:002286)
China · Delayed Price · Currency is CNY 7.96
-0.05 (-0.62%)
Aug 4, 2026, 3:04 PM CST
Baolingbao Biology Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,029 | 3,402 | 2,729 | 3,011 | 3,380 | 5,028 | |
Market Cap Growth | -24.17% | 24.68% | -9.36% | -10.92% | -32.78% | 19.45% |
Enterprise Value | 2,972 | 3,335 | 2,816 | 3,117 | 3,446 | 4,715 |
Last Close Price | 7.96 | 8.80 | 7.23 | 7.82 | 8.67 | 12.82 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 19.29 | 22.59 | 24.55 | 55.79 | 25.38 | 24.94 |
Forward PE | 15.02 | 16.71 | 10.69 | 10.69 | 10.69 | 22.67 |
PS Ratio | 1.08 | 1.24 | 1.14 | 1.19 | 1.25 | 1.82 |
PB Ratio | 1.32 | 1.52 | 1.34 | 1.52 | 1.69 | 2.77 |
P/TBV Ratio | 1.38 | 1.61 | 1.42 | 1.62 | 1.80 | 2.99 |
P/FCF Ratio | 53.49 | 48.56 | 46.42 | 23.15 | - | 44.33 |
P/OCF Ratio | 11.63 | 13.12 | 10.97 | 10.67 | 109.66 | 24.38 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.06 | 1.21 | 1.17 | 1.24 | 1.27 | 1.71 |
EV/EBITDA Ratio | 10.09 | 11.47 | 10.75 | 17.55 | 13.36 | 14.83 |
EV/EBIT Ratio | 17.07 | 19.34 | 19.60 | 52.14 | 22.01 | 22.14 |
EV/FCF Ratio | 52.49 | 47.59 | 47.90 | 23.97 | - | 41.58 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.10 | 0.06 | 0.14 | 0.15 | 0.26 | 0.23 |
Debt / EBITDA Ratio | 0.78 | 0.43 | 1.07 | 1.67 | 1.97 | 1.30 |
Debt / FCF Ratio | 4.03 | 1.81 | 4.81 | 2.34 | - | 3.63 |
Net Debt / Equity Ratio | -0.02 | -0.07 | 0.01 | 0.03 | 0.07 | -0.15 |
Net Debt / EBITDA Ratio | -0.20 | -0.52 | 0.11 | 0.35 | 0.55 | -0.88 |
Net Debt / FCF Ratio | -1.01 | -2.14 | 0.47 | 0.47 | -0.63 | -2.47 |
Asset Turnover | 0.99 | 1.01 | 0.90 | 0.89 | 0.90 | 0.98 |
Inventory Turnover | 7.50 | 7.83 | 7.49 | 7.58 | 7.75 | 9.56 |
Quick Ratio | 1.11 | 1.17 | 0.88 | 0.87 | 0.83 | 0.89 |
Current Ratio | 1.79 | 1.89 | 1.41 | 1.36 | 1.31 | 1.17 |
Return on Equity (ROE) | 7.03% | 7.05% | 5.52% | 2.71% | 6.98% | 11.81% |
Return on Assets (ROA) | 3.80% | 3.95% | 3.37% | 1.32% | 3.24% | 4.72% |
Return on Invested Capital (ROIC) | 6.75% | 7.04% | 5.92% | 2.37% | 7.24% | 12.54% |
Return on Capital Employed (ROCE) | 7.30% | 7.50% | 6.80% | 2.90% | 7.00% | 11.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 5.10% | 4.43% | 4.07% | 1.79% | 3.94% | 4.01% |
FCF Yield | 1.87% | 2.06% | 2.15% | 4.32% | -6.62% | 2.26% |
Dividend Yield | 1.50% | 1.36% | 1.31% | 1.02% | 0.92% | 0.47% |
Payout Ratio | 19.93% | 21.20% | 49.76% | 92.20% | 39.43% | 19.32% |
Buyback Yield / Dilution | -2.80% | 0.85% | -2.99% | 2.74% | 0.91% | -4.81% |
Total Shareholder Return | -1.31% | 2.21% | -1.67% | 3.76% | 1.83% | -4.34% |